BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ossig C, Reichmann H. Treatment Strategies in Early and Advanced Parkinson Disease. Neurologic Clinics 2015;33:19-37. [DOI: 10.1016/j.ncl.2014.09.009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Ma C, Zhang P, Pan L, Li X, Yin C, Li A, Zong R, Zhang Z. A feature fusion sequence learning approach for quantitative analysis of tremor symptoms based on digital handwriting. Expert Systems with Applications 2022;203:117400. [DOI: 10.1016/j.eswa.2022.117400] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ma C, Zhang P, Wang J, Zhang J, Pan L, Li X, Yin C, Li A, Zong R, Zhang Z. Objective Quantification of the Severity of Postural Tremor Based on Kinematic Parameters: A Multi-Sensory Fusion Study. Computer Methods and Programs in Biomedicine 2022. [DOI: 10.1016/j.cmpb.2022.106741] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Jo A, Lee Y, Kam TI, Kang SU, Neifert S, Karuppagounder SS, Khang R, Kang H, Park H, Chou SC, Oh S, Jiang H, Swing DA, Ham S, Pirooznia S, Umanah GKE, Mao X, Kumar M, Ko HS, Kang HC, Lee BD, Lee YI, Andrabi SA, Park CH, Lee JY, Kim H, Kim H, Kim H, Cho JW, Paek SH, Na CH, Tessarollo L, Dawson VL, Dawson TM, Shin JH. PARIS farnesylation prevents neurodegeneration in models of Parkinson's disease. Sci Transl Med 2021;13:eaax8891. [PMID: 34321320 DOI: 10.1126/scitranslmed.aax8891] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
4 Grecco CF, Miranda LFC, Costa Queiroz ME. Aminopropyl hybrid silica monolithic capillary containing mesoporous SBA-15 particles for in-tube SPME-HILIC-MS/MS to determine levodopa, carbidopa, benserazide, dopamine, and 3-O-methyldopa in plasma samples. Microchemical Journal 2020;157:105106. [DOI: 10.1016/j.microc.2020.105106] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
5 Terrens AF, Soh SE, Morgan P. The safety and feasibility of a Halliwick style of aquatic physiotherapy for falls and balance dysfunction in people with Parkinson's Disease: A single blind pilot trial. PLoS One 2020;15:e0236391. [PMID: 32730325 DOI: 10.1371/journal.pone.0236391] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
6 Liao X, Wu N, Liu D, Shuai B, Li S, Li K. Levodopa/carbidopa/entacapone for the treatment of early Parkinson's disease: a meta-analysis. Neurol Sci 2020;41:2045-54. [PMID: 32162166 DOI: 10.1007/s10072-020-04303-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
7 Riesenberg R, Werth J, Zhang Y, Duvvuri S, Gray D. PF-06649751 efficacy and safety in early Parkinson's disease: a randomized, placebo-controlled trial. Ther Adv Neurol Disord 2020;13:1756286420911296. [PMID: 32201505 DOI: 10.1177/1756286420911296] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
8 Nunes SFL, Alvarez AM, Valcarenghi RV, Hammerschmidt KSDA, Baptista R. Adaptação dos Familiares Cuidadores de Idosos com Doença de Parkinson: Processo de Transição. Psic : Teor e Pesq 2019;35:e35nspe4. [DOI: 10.1590/0102.3772e35nspe4] [Reference Citation Analysis]
9 Rovini E, Maremmani C, Cavallo F. Automated Systems Based on Wearable Sensors for the Management of Parkinson's Disease at Home: A Systematic Review. Telemed J E Health 2019;25:167-83. [PMID: 29969384 DOI: 10.1089/tmj.2018.0035] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
10 Xu JJ, Yang ST, Sha Y, Ge YY, Wang JM. Hyperbaric oxygen treatment for Parkinson's disease with severe depression and anxiety: A case report. Medicine (Baltimore) 2018;97:e0029. [PMID: 29489651 DOI: 10.1097/MD.0000000000010029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
11 Capriotti T, Terzakis K. Parkinson Disease. Home Healthc Now. 2016;34:300-307. [PMID: 27243427 DOI: 10.1097/nhh.0000000000000398] [Cited by in Crossref: 16] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
12 Rovini E, Maremmani C, Cavallo F. How Wearable Sensors Can Support Parkinson's Disease Diagnosis and Treatment: A Systematic Review. Front Neurosci 2017;11:555. [PMID: 29056899 DOI: 10.3389/fnins.2017.00555] [Cited by in Crossref: 138] [Cited by in F6Publishing: 137] [Article Influence: 27.6] [Reference Citation Analysis]
13 Terrens AF, Soh S, Morgan PE. The efficacy and feasibility of aquatic physiotherapy for people with Parkinson’s disease: a systematic review. Disability and Rehabilitation 2018;40:2847-56. [DOI: 10.1080/09638288.2017.1362710] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
14 Mittal SO, Machado D, Richardson D, Dubey D, Jabbari B. Botulinum Toxin in Parkinson Disease Tremor: A Randomized, Double-Blind, Placebo-Controlled Study With a Customized Injection Approach. Mayo Clin Proc 2017;92:1359-67. [PMID: 28789780 DOI: 10.1016/j.mayocp.2017.06.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
15 Jones B, Hopkins G, Wherry SA, Lueck CJ, Das CP, Dugdale P. Evaluation of a Regional Australian Nurse-Led Parkinson's Service Using the Context, Input, Process, and Product Evaluation Model. Clin Nurse Spec 2016;30:264-70. [PMID: 27509562 DOI: 10.1097/NUR.0000000000000232] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
16 Sever M, Turkyilmaz M, Sevinc C, Cakir A, Ocalan B, Cansev M, Guler MO, Tekinay AB. Regenerative effects of peptide nanofibers in an experimental model of Parkinson's disease. Acta Biomater 2016;46:79-90. [PMID: 27619838 DOI: 10.1016/j.actbio.2016.09.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
17 Réus GZ, Titus SE, Abelaira HM, Freitas SM, Tuon T, Quevedo J, Budni J. Neurochemical correlation between major depressive disorder and neurodegenerative diseases. Life Sciences 2016;158:121-9. [DOI: 10.1016/j.lfs.2016.06.027] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
18 Bayer Andersen K, Leander Johansen J, Hentzer M, Smith GP, Dietz GP. Protection of Primary Dopaminergic Midbrain Neurons by GPR139 Agonists Supports Different Mechanisms of MPP(+) and Rotenone Toxicity. Front Cell Neurosci 2016;10:164. [PMID: 27445691 DOI: 10.3389/fncel.2016.00164] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
19 Choi JG, Park G, Kim HG, Oh DS, Kim H, Oh MS. In Vitro and in Vivo Neuroprotective Effects of Walnut (Juglandis Semen) in Models of Parkinson's Disease. Int J Mol Sci 2016;17:E108. [PMID: 26784178 DOI: 10.3390/ijms17010108] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
20 Crispo JAG, Willis AW, Thibault DP, Fortin Y, Emons M, Bjerre LM, Kohen DE, Perez-Lloret S, Mattison D, Krewski D. Associations Between Cardiovascular Events and Nonergot Dopamine Agonists in Parkinson's Disease. Mov Disord Clin Pract 2016;3:257-67. [PMID: 30363519 DOI: 10.1002/mdc3.12286] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
21 Kim J, Sidransky E, Lopez G. Understanding and managing parkinsonism in patients with glucocerebrosidase mutations. Expert Opinion on Orphan Drugs 2015;3:549-62. [DOI: 10.1517/21678707.2015.1034271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
22 Lancioni G, Singh N, O'reilly M, Sigafoos J, D'amico F, Sasanelli G, Denitto F, Lang R. Technology-aided leisure and communication: Opportunities for persons with advanced Parkinson’s disease. Developmental Neurorehabilitation 2015;19:398-404. [DOI: 10.3109/17518423.2014.1002637] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
23 Vanhauwaert R, Verstreken P. Flies with Parkinson's disease. Exp Neurol 2015;274:42-51. [PMID: 25708988 DOI: 10.1016/j.expneurol.2015.02.020] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]